

Klaus Dembowsky, MD, PhD.

CEO amcure GmbH

Hermann-von-Helmholtz-Platz 1
76344 Eggenstein-Leopoldshafen, Germany
E-mail: klaus.dembowsky@amcure.com

After his medical studies he was trained in neurophysiology at the University of Heidelberg and performed innovative basic research on the autonomic nervous system and its role in the control of the cardiovascular system. In the early 1990ies Klaus Dembowsky joined the cardiovascular research institute at Bayer in Wuppertal (Germany). He brought several novel compounds for treating cardiovascular disease into clinical development, two of them are marketed. During his time at Bayer he was also part of the Bayer Millennium collaboration for novel targets and worked on site at Millennium in Cambridge (USA).

Having been inspired by the Biotech industry in the greater Boston area Klaus then joined Ingenium Pharmaceuticals (VP Drug Discovery) in Munich (Germany) and established an innovative project for inflammatory diseases. Next step in his career was Managing Director at Speedel Experimenta in Allschwil (Switzerland) where he was in charge of drug discovery and preclinical development of novel cardiovascular drugs. He then joined Polyphor (Allschwil, Switzerland) as Chief Medical Officer. At Polyphor he brought three peptidergic drugs into clinical development for different therapeutic areas.

In 2015 he joined the start-up company amcure (Germany) as CEO and formed a small Biotech company with internal preclinical and clinical activities. Under his leadership the first clinical study with the innovative CD44v6 inhibitor AMC303 in cancer patients was completed in 2020.

His focus is on identifying and developing novel drugs for the benefits of patients with diseases where there is a high unmet medical need. Over time Klaus Dembowsky has developed an extensive network of clinical investigators, academic clinicians and colleagues in the Biotech and Pharma industry. In all positions with increasing responsibilities, he was also part of executive management and strongly and with success involved in funds raising from investors and by grants and in business development.